Caribou Biosciences(US:CRBU) ZACKSยท2024-08-06 15:05Company Overview - Caribou Biosciences, Inc. (CRBU) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2024 [1] - The consensus estimate indicates a quarterly loss of $0.45 per share, reflecting a year-over-year change of +6.3% [3] - Revenues are projected to be $3.31 million, down 12% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 1.08% higher over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Caribou Biosciences is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.67% [10] - The stock currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [10] Earnings Surprise History - In the last reported quarter, Caribou Biosciences was expected to post a loss of $0.39 per share but actually reported a loss of $0.46, resulting in a surprise of -17.95% [11] - Over the last four quarters, the company has beaten consensus EPS estimates two times [12] Industry Context - Fortrea Holdings Inc. (FTRE), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post earnings of $0.07 per share for the quarter ended June 2024, indicating a year-over-year change of -86.5% [16] - Fortrea's revenue is expected to be $686.08 million, down 13.5% from the previous year [16] - The consensus EPS estimate for Fortrea has been revised 2.7% higher over the last 30 days, but it has an Earnings ESP of -17.91% [17]